Kalexo Bio
Mabwell and Aditum Launch Kalexo Bio to Advance Dual-Target siRNA Therapy in “NewCo” Spinout
Mabwell Bioscience and Aditum Bio launch Kalexo Bio, a NewCo spinout to develop 2MW7141, a dual-target siRNA therapy for dyslipidemia and high-risk cardiovascular disease. Deal includes $12M upfront, preferred shares, and up to $1B in milestones.